Signaturefd LLC Grows Stake in Thermo Fisher Scientific Inc. (TMO)
Signaturefd LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,771 shares of the medical research company’s stock after purchasing an additional 540 shares during the period. Signaturefd LLC’s holdings in Thermo Fisher Scientific were worth $574,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Paloma Partners Management Co lifted its stake in shares of Thermo Fisher Scientific by 1,294.5% in the second quarter. Paloma Partners Management Co now owns 2,036 shares of the medical research company’s stock worth $421,000 after acquiring an additional 1,890 shares during the period. Highland Capital Management LP lifted its stake in Thermo Fisher Scientific by 7.0% in the second quarter. Highland Capital Management LP now owns 13,915 shares of the medical research company’s stock valued at $2,883,000 after buying an additional 915 shares during the period. SNS Financial Group LLC lifted its stake in Thermo Fisher Scientific by 43.0% in the second quarter. SNS Financial Group LLC now owns 1,461 shares of the medical research company’s stock valued at $302,000 after buying an additional 439 shares during the period. Flagship Harbor Advisors LLC lifted its stake in Thermo Fisher Scientific by 15.7% in the second quarter. Flagship Harbor Advisors LLC now owns 5,333 shares of the medical research company’s stock valued at $1,104,000 after buying an additional 722 shares during the period. Finally, Tuttle Tactical Management acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $430,000. Institutional investors own 85.96% of the company’s stock.
In other news, CEO Marc N. Casper sold 45,000 shares of the company’s stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $214.80, for a total transaction of $9,666,000.00. Following the transaction, the chief executive officer now directly owns 315,122 shares of the company’s stock, valued at $67,688,205.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $233.95, for a total value of $11,697,500.00. Following the transaction, the chief executive officer now directly owns 320,122 shares in the company, valued at $74,892,541.90. The disclosure for this sale can be found here. Insiders have sold 115,550 shares of company stock worth $26,169,529 over the last ninety days. 0.49% of the stock is owned by insiders.
Shares of NYSE:TMO opened at $236.43 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.11 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a twelve month low of $181.51 and a twelve month high of $240.88. The company has a market cap of $95.04 billion, a PE ratio of 24.91, a PEG ratio of 1.72 and a beta of 1.13.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 25th. The medical research company reported $2.75 earnings per share for the quarter, topping analysts’ consensus estimates of $2.63 by $0.12. Thermo Fisher Scientific had a return on equity of 16.28% and a net margin of 10.36%. The company had revenue of $6.08 billion for the quarter, compared to analyst estimates of $5.90 billion. During the same period in the prior year, the firm earned $2.30 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 21.8% on a year-over-year basis. equities analysts predict that Thermo Fisher Scientific Inc. will post 10.98 EPS for the current fiscal year.
Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback program on Friday, September 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.1% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 15th. Stockholders of record on Monday, September 17th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, September 14th. Thermo Fisher Scientific’s payout ratio is 7.17%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.